O2 RegenTech, with a valuation of $6.8 million, is raising funds on NetCapital. The company is using its proprietary biopolymer technology to commercialize easy-to-use wound care solutions. O2 RegenTech’s first product is called OXAID and is a moist, oxygenating, and antimicrobial dressing that promotes chronic wound healing. It is a one-of-a-kind wound solution that is cost-effective and easy to use and helps chronic wounds heal faster and at a lower cost than other oxygen delivery systems. Dr. Andreas Inmann and Dr. Nic Leipzig founded O2 RegenTech in July 2013. The current crowdfunding campaign has a minimum target of $10,002.80 and a maximum target of $612,000. The campaign proceeds will be used for product development, regulatory affairs, operations, payroll, and biocompatibility testing.